HC Wainwright Issues Pessimistic Forecast for GH Research (NASDAQ:GHRS) Stock Price

GH Research (NASDAQ:GHRS – Get Free Report) had its price objective lowered by equities research analysts at HC Wainwright from $65.00 to $55.00 in a report issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright‘s price target would suggest a potential upside of 193.33% from the stock’s current price.

GHRS has been the subject of a number of other research reports. Cantor Fitzgerald increased their price objective on shares of GH Research from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. New Street Research set a $65.00 target price on shares of GH Research in a research report on Monday, August 10th. Wells Fargo & Company initiated coverage on shares of GH Research in a research note on Monday, July 27th. They issued an “overweight” rating and a $44.00 target price on the stock. Guggenheim increased their price target on shares of GH Research from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Stifel Nicolaus set a $38.00 price target on shares of GH Research in a research report on Friday. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.45.

Check Out Our Latest Research Report on GHRS

GH Research Trading Down 1.8%

Shares of NASDAQ GHRS opened at $18.75 on Tuesday. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of -19.74 and a beta of 1.31. GH Research has a one year low of $12.04 and a one year high of $31.44. The business has a fifty day simple moving average of $22.11 and a 200 day simple moving average of $21.65.

GH Research (NASDAQ:GHRS – Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.13. On average, research analysts anticipate that GH Research will post -1.20 earnings per share for the current fiscal year.

Institutional Trading of GH Research

A number of large investors have recently bought and sold shares of GHRS. Braidwell LP bought a new position in shares of GH Research during the second quarter valued at $5,571,000. Troluce Capital Advisors LLC boosted its stake in shares of GH Research by 165.4% in the 1st quarter. Troluce Capital Advisors LLC now owns 990,472 shares of the company’s stock valued at $13,926,000 after purchasing an additional 617,260 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of GH Research in the 2nd quarter worth about $495,000. Renaissance Technologies LLC bought a new stake in shares of GH Research in the 1st quarter worth about $290,000. Finally, Bellevue Group AG acquired a new stake in shares of GH Research during the 3rd quarter worth about $109,000. 56.90% of the stock is currently owned by institutional investors.

GH Research Company Profile

(Get Free Report)

GH Research plc is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders. The company is based in Dublin, Ireland, and its research centers on mebufotenin, also known as 5-MeO-DMT. Its lead investigational candidate, GH001, is an inhaled formulation being studied for treatment-resistant depression. GH Research is also developing other mebufotenin-based candidates and delivery approaches. These treatments remain investigational and are not approved for general use.

Read More

Analyst Recommendations for GH Research (NASDAQ:GHRS)

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.